TFPI Antibody (G-6): sc-133139
- TFPI Antibody (G-6) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against amino acids 31-150 mapping near the N-terminus of TFPI of human origin
- recommended for detection of precursor and mature forms of TFPI of human origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for TFPI Antibody (G-6) for WB applications. These reagents are now offered in bundles with TFPI Antibody (G-6) (see ordering information below).
QUICK LINKS
TFPI Antibody (G-6) is a mouse monoclonal IgG1 antibody that detects tissue factor pathway inhibitor (TFPI) in human samples through western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). TFPI plays a crucial role in the regulation of blood coagulation by inhibiting the extrinsic pathway, which is vital for maintaining hemostasis and preventing excessive clot formation. TFPI primarily circulates in the bloodstream in association with lipoproteins such as very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL). TFPI presence in the plasma is essential for function, acting to inhibit factor Xa and the tissue factor-factor VIIa complex, thereby preventing inappropriate clotting in response to vascular injury. Additionally, TFPI is a multivalent, Kunitz-type proteinase inhibitor, and TFPI′s ability to interact with various plasma components underscores importance in the coagulation cascade. Anti-TFPI antibody (G-6) is an invaluable tool for researchers studying coagulation pathways and related disorders, providing insights into the mechanisms of hemostasis and potential therapeutic targets.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
TFPI Antibody (G-6) References:
- TFPI gene variation and ischemic stroke. | Pedersen, A., et al. 2012. Thromb Res. 130: 565-7. PMID: 22749962
- Increased expression of TFPI in human carotid stenosis. | Stavik, B., et al. 2017. Thromb Res. 155: 31-37. PMID: 28482260
- Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab. | Chowdary, P. 2018. Drugs. 78: 881-890. PMID: 29845491
- Insights into the Functional Role of ADTRP (Androgen-Dependent TFPI-Regulating Protein) in Health and Disease. | Lupu, C., et al. 2021. Int J Mol Sci. 22: PMID: 33923232
- TFPI inhibits breast cancer progression by suppressing ERK/p38 MAPK signaling pathway. | Xing, M., et al. 2022. Genes Genomics. 44: 801-812. PMID: 35567715
- TFPI and FXIII negatively and S100A8/A9 and Cystatin C positively correlate with D-dimer in COVID-19. | Gupta, A., et al. 2022. Exp Biol Med (Maywood). 247: 1570-1576. PMID: 35723053
- Mutations of TFPI-binding exosites on factor VII cause bleeding phenotypes in factor VII deficiency. | Seanoon, K., et al. 2022. Blood Adv. 6: 5887-5897. PMID: 35973191
- Identification of TFPI as a receptor reveals recombination-driven receptor switching in Clostridioides difficile toxin B variants. | Tian, S., et al. 2022. Nat Commun. 13: 6786. PMID: 36351897
- Longitudinal observations of TFPI levels in paediatric Haemophilia A patients. | Schwers, S., et al. 2023. Haemophilia. 29: 1142-1149. PMID: 37335569
- TFPI from erythroblasts drives heme production in central macrophages promoting erythropoiesis in polycythemia. | Ma, JK., et al. 2024. Nat Commun. 15: 3976. PMID: 38729948
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TFPI Antibody (G-6) | sc-133139 | 200 µg/ml | $322.00 | |||
TFPI Antibody (G-6): m-IgG Fc BP-HRP Bundle | sc-539854 | 200 µg Ab; 10 µg BP | $361.00 | |||
TFPI Antibody (G-6): m-IgG1 BP-HRP Bundle | sc-541748 | 200 µg Ab; 20 µg BP | $361.00 |